Diamyd Medical AB (publ) - Asset Resilience Ratio

Latest as of February 2026: 75.20%

Diamyd Medical AB (publ) (DMYD-B) has an Asset Resilience Ratio of 75.20% as of February 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.

Liquid Assets

Skr190.73 Million

≈ $20.53 Million USD Cash + Short-term Investments

Total Assets

Skr253.63 Million

≈ $27.29 Million USD All company assets

Resilience Assessment

Very High

Financial Resilience Level

Asset Resilience Ratio Trend (2011–2025)

This chart shows how Diamyd Medical AB (publ)'s Asset Resilience Ratio has changed over time. Check how strategically is Diamyd Medical AB (publ)'s equity deployed to assess the company's strategic physical and investment asset allocation.

Liquid Assets Composition Over Time

This chart breaks down Diamyd Medical AB (publ)'s liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see how much is Diamyd Medical AB (publ) worth.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	Skr150.94 Million	59.51%
Short-term Investments	Skr39.79 Million	15.69%
Total Liquid Assets	Skr190.73 Million	75.20%

Asset Resilience Insights

Very High Liquidity: Diamyd Medical AB (publ) maintains exceptional liquid asset reserves at 75.20% of total assets.
This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
The company primarily holds liquidity in cash and equivalents rather than short-term investments.

Diamyd Medical AB (publ) Industry Peers by Asset Resilience Ratio

Compare Diamyd Medical AB (publ)'s asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Tubize-Fin BR:TUB	Biotechnology	0.05%
Verona Pharma plc F:I9SA	Biotechnology	0.00%
Xiamen Amoytop Biotech Co Ltd SHG:688278	Biotechnology	4.69%
Syndax Pharmaceuticals Inc NASDAQ:SNDX	Biotechnology	46.79%
Neuren Pharmaceuticals Ltd AU:NEU	Biotechnology	90.43%
Vor Biopharma Inc NASDAQ:VOR	Biotechnology	63.47%
Chengdu Kanghua Biological Products SHE:300841	Biotechnology	1.19%
Jiangsu Aidea Pharmaceutical Co Ltd SHG:688488	Biotechnology	4.35%

Annual Asset Resilience Ratio for Diamyd Medical AB (publ) (2011–2025)

The table below shows the annual Asset Resilience Ratio data for Diamyd Medical AB (publ).

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2025-08-31	78.60%	Skr277.19 Million ≈ $29.83 Million	Skr352.64 Million ≈ $37.95 Million	+17.62pp
2024-08-31	60.99%	Skr132.37 Million ≈ $14.24 Million	Skr217.04 Million ≈ $23.36 Million	-0.70pp
2023-08-31	61.69%	Skr126.96 Million ≈ $13.66 Million	Skr205.81 Million ≈ $22.15 Million	-5.82pp
2022-08-31	67.51%	Skr159.67 Million ≈ $17.18 Million	Skr236.52 Million ≈ $25.45 Million	-1.68pp
2021-08-31	69.19%	Skr139.38 Million ≈ $15.00 Million	Skr201.44 Million ≈ $21.68 Million	-6.97pp
2020-08-31	76.16%	Skr68.36 Million ≈ $7.36 Million	Skr89.76 Million ≈ $9.66 Million	-0.27pp
2019-08-31	76.43%	Skr56.71 Million ≈ $6.10 Million	Skr74.20 Million ≈ $7.99 Million	-3.80pp
2018-08-31	80.23%	Skr44.11 Million ≈ $4.75 Million	Skr54.98 Million ≈ $5.92 Million	-6.67pp
2017-08-31	86.90%	Skr85.72 Million ≈ $9.23 Million	Skr98.65 Million ≈ $10.62 Million	+3.79pp
2016-08-31	83.11%	Skr31.40 Million ≈ $3.38 Million	Skr37.78 Million ≈ $4.07 Million	+55.24pp
2015-08-31	27.87%	Skr13.00 Million ≈ $1.40 Million	Skr46.65 Million ≈ $5.02 Million	+6.39pp
2014-08-31	21.48%	Skr10.96 Million ≈ $1.18 Million	Skr51.02 Million ≈ $5.49 Million	-29.70pp
2012-08-31	51.18%	Skr215.85 Million ≈ $23.23 Million	Skr421.74 Million ≈ $45.39 Million	-2.29pp
2011-08-31	53.48%	Skr277.86 Million ≈ $29.90 Million	Skr519.60 Million ≈ $55.92 Million	--

pp = percentage points

About Diamyd Medical AB (publ)

ST:DMYD-B Sweden Biotechnology

Market Cap

$14.94 Million

Skr138.82 Million SEK

Market Cap Rank

#25971 Global

#539 in Sweden

Share Price

Skr1.04

Change (1 day)

+0.58%

52-Week Range

Skr1.01 - Skr17.62

All Time High

Skr71.00